Oric Pharmaceuticals Stock Net Income
| ORIC Stock | USD 12.25 0.26 2.17% |
As of the 26th of January, Oric Pharmaceuticals holds the Risk Adjusted Performance of 0.0117, semi deviation of 3.06, and Coefficient Of Variation of 20174.57. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oric Pharmaceuticals, as well as the relationship between them.
Oric Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Oric Pharmaceuticals' valuation are provided below:We have found one hundred twenty available trending fundamental ratios for Oric Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. Investors should ensure to check out all of Oric Pharmaceuticals' recent performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of January 26, 2026, Market Cap is expected to decline to about 635.9 M. In addition to that, Enterprise Value is expected to decline to about 579.3 M This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -80.2 M | -84.2 M | |
| Net Loss | -115.1 M | -109.3 M | |
| Net Loss | -115.1 M | -120.8 M | |
| Net Loss | (2.11) | (2.21) |
Oric | Net Income | Build AI portfolio with Oric Stock |
Latest Oric Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Oric Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Oric Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Oric Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Oric Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oric Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (127.85 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Oric Net Income Regression Statistics
| Arithmetic Mean | (53,993,852) | |
| Coefficient Of Variation | (75.49) | |
| Mean Deviation | 37,113,002 | |
| Median | (22,029,000) | |
| Standard Deviation | 40,759,759 | |
| Sample Variance | 1661.4T | |
| Range | 106.5M | |
| R-Value | (0.89) | |
| Mean Square Error | 377.7T | |
| R-Squared | 0.79 | |
| Slope | (7,159,903) | |
| Total Sum of Squares | 26581.7T |
Oric Net Income History
Other Fundumenentals of Oric Pharmaceuticals
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Oric Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Oric Pharmaceuticals is extremely important. It helps to project a fair market value of Oric Stock properly, considering its historical fundamentals such as Net Income. Since Oric Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Oric Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Oric Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oric Pharmaceuticals. If investors know Oric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oric Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Oric Pharmaceuticals is measured differently than its book value, which is the value of Oric that is recorded on the company's balance sheet. Investors also form their own opinion of Oric Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oric Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oric Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oric Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oric Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oric Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Oric Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Oric Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Oric Pharmaceuticals.
| 10/28/2025 |
| 01/26/2026 |
If you would invest 0.00 in Oric Pharmaceuticals on October 28, 2025 and sell it all today you would earn a total of 0.00 from holding Oric Pharmaceuticals or generate 0.0% return on investment in Oric Pharmaceuticals over 90 days. Oric Pharmaceuticals is related to or competes with Amylyx Pharmaceuticals, Relay Therapeutics, Precigen, Nektar Therapeutics, Inhibrx Biosciences, Syndax Pharmaceuticals, and Terns Pharmaceuticals. ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment o... More
Oric Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Oric Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Oric Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.24 | |||
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 15.34 | |||
| Value At Risk | (4.36) | |||
| Potential Upside | 6.63 |
Oric Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oric Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Oric Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Oric Pharmaceuticals historical prices to predict the future Oric Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0117 | |||
| Jensen Alpha | (0.06) | |||
| Total Risk Alpha | (0.34) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.008 |
Oric Pharmaceuticals January 26, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0117 | |||
| Market Risk Adjusted Performance | 0.018 | |||
| Mean Deviation | 2.76 | |||
| Semi Deviation | 3.06 | |||
| Downside Deviation | 3.24 | |||
| Coefficient Of Variation | 20174.57 | |||
| Standard Deviation | 3.71 | |||
| Variance | 13.78 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.06) | |||
| Total Risk Alpha | (0.34) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.008 | |||
| Maximum Drawdown | 15.34 | |||
| Value At Risk | (4.36) | |||
| Potential Upside | 6.63 | |||
| Downside Variance | 10.5 | |||
| Semi Variance | 9.38 | |||
| Expected Short fall | (3.39) | |||
| Skewness | 0.6916 | |||
| Kurtosis | 1.45 |
Oric Pharmaceuticals Backtested Returns
Oric Pharmaceuticals maintains Sharpe Ratio (i.e., Efficiency) of -0.0319, which implies the firm had a -0.0319 % return per unit of risk over the last 3 months. Oric Pharmaceuticals exposes thirty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Oric Pharmaceuticals' Risk Adjusted Performance of 0.0117, coefficient of variation of 20174.57, and Semi Deviation of 3.06 to confirm the risk estimate we provide. The company holds a Beta of 1.05, which implies a somewhat significant risk relative to the market. Oric Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Oric Pharmaceuticals is expected to follow. At this point, Oric Pharmaceuticals has a negative expected return of -0.12%. Please make sure to check Oric Pharmaceuticals' jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to decide if Oric Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.73 |
Almost perfect reverse predictability
Oric Pharmaceuticals has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Oric Pharmaceuticals time series from 28th of October 2025 to 12th of December 2025 and 12th of December 2025 to 26th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Oric Pharmaceuticals price movement. The serial correlation of -0.73 indicates that around 73.0% of current Oric Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.73 | |
| Spearman Rank Test | -0.55 | |
| Residual Average | 0.0 | |
| Price Variance | 2.61 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Oric Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Oric Pharmaceuticals reported net income of (127.85 Million). This is 137.46% lower than that of the Biotechnology sector and 282.52% lower than that of the Health Care industry. The net income for all United States stocks is 122.39% higher than that of the company.
Oric Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oric Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oric Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Oric Pharmaceuticals by comparing valuation metrics of similar companies.Oric Pharmaceuticals is currently under evaluation in net income category among its peers.
Oric Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Oric Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Oric Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Oric Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Oric Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Oric Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Oric Pharmaceuticals' value.| Shares | Point72 Asset Management, L.p. | 2025-06-30 | 2.9 M | T. Rowe Price Associates, Inc. | 2025-06-30 | 2.8 M | Fmr Inc | 2025-06-30 | 2.5 M | First Turn Management Llc | 2025-06-30 | 2 M | Silverarc Capital Management, Llc | 2025-06-30 | 1.8 M | Balyasny Asset Management Llc | 2025-06-30 | 1.8 M | Mpm Oncology Impact Management Lp | 2025-06-30 | 1.7 M | State Street Corp | 2025-06-30 | 1.6 M | Ecor1 Capital, Llc | 2025-06-30 | 1.6 M | Nextech Invest, Ltd. | 2025-06-30 | 7.2 M | Vr Adviser, Llc | 2025-06-30 | 6.6 M |
Oric Fundamentals
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 883.86 M | ||||
| Shares Outstanding | 97.39 M | ||||
| Shares Owned By Insiders | 6.71 % | ||||
| Shares Owned By Institutions | 93.29 % | ||||
| Number Of Shares Shorted | 21.47 M | ||||
| Price To Book | 2.87 X | ||||
| EBITDA | (126.74 M) | ||||
| Net Income | (127.85 M) | ||||
| Cash And Equivalents | 227.06 M | ||||
| Cash Per Share | 5.74 X | ||||
| Total Debt | 3.18 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 18.72 X | ||||
| Book Value Per Share | 4.18 X | ||||
| Cash Flow From Operations | (112.66 M) | ||||
| Short Ratio | 14.98 X | ||||
| Earnings Per Share | (1.71) X | ||||
| Target Price | 21.0 | ||||
| Number Of Employees | 106 | ||||
| Beta | 1.36 | ||||
| Market Capitalization | 1.17 B | ||||
| Total Asset | 274.14 M | ||||
| Retained Earnings | (562.77 M) | ||||
| Working Capital | 237.4 M | ||||
| Net Asset | 274.14 M |
About Oric Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oric Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oric Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oric Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Oric Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oric Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oric Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oric Pharmaceuticals Stock:Check out Oric Pharmaceuticals Piotroski F Score and Oric Pharmaceuticals Altman Z Score analysis. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oric Pharmaceuticals. If investors know Oric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oric Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Oric Pharmaceuticals is measured differently than its book value, which is the value of Oric that is recorded on the company's balance sheet. Investors also form their own opinion of Oric Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oric Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oric Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oric Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oric Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oric Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.